Brand name: Imjudo TM
Active ingredients: tremelimumab
What it is used for
Hepatocellular Carcinoma (HCC),IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.
How to take it
The way to take this medicine is: Intravenous Infusion.
- Store at 2 to 8 degrees Celsius
- Refrigerate
- Do not Freeze
- Shelf lifetime is 48 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme